Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | NCF1 | P14598 | 1/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAT | P00750 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14417956 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL19992007 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| Decarboxylated Derivative SCHEMBL5183307 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL15444322 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL131302 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL469120 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL10990399 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL12252084 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL22078896 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT | |
| SCHEMBL18102722 | 1.00 | CYP2D6 (0.54) | CYP2D6SIGMAR1NCF1PLGPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017567-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | NAUTILUS SUBSIDIARY, INC. | 2022-01-20 | — | — | US | disclosed |
| US-10035790-B2 | RORγ modulators | EXELIXIS, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20150266856-A1 | RORGamma Modulators | EXELIXIS, INC. | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266856-A1 | RORGamma Modulators | RORB, RORA, RORC | CYP2D6 1331/4885SIGMAR1 694/4885NCF1 772/4885 |
| US-10035790-B2 | RORγ modulators | RORB, RORA, RORC | CYP2D6 626/4885SIGMAR1 581/4885NCF1 852/4885 |
| US-20220017567-A1 | METHODS OF GENERATING NANOARRAYS AND MICROARRAYS | NAPA, SSBP1, NASP | CYP2D6 4865/4885SIGMAR1 2645/4885NCF1 187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.